Eastern Cooperative Oncology Group

A phase III multicenter, randomized, open-label study in China (Jan 2021-Jun 2022) evaluated DEB-TACE alone vs. DEB-TACE + apatinib for uHCC. Eligibility criteria included BCLC stage B-C, age 18-75, ECOG PS 0-1, and liver tumor <60% of total liver volume. DEB-TACE was standardized, with apatinib administered orally post-TACE. Treatment efficacy was assessed via mRECIST criteria, with PFS and OS as primary endpoints. Sample size estimation required 233 participants, with statistical analysis using Cox Frailty models to account for center effects.

Fox Chase study finds 79% success in organ preservation for lower rectal cancer patients with node-negative tumors using neoadjuvant chemotherapy and local excision, with no local recurrences reported at 24 months median follow-up.

FDA approves Optune Lua® for concurrent use with PD-1/PD-L1 inhibitors or docetaxel in metastatic NSCLC patients who have progressed on platinum-based therapy. The phase III LUNAR trial showed a 3.3-month extension in median overall survival with tumor treating fields therapy. Device-related adverse events were mostly grade 1 or 2.

This study assessed MR-guided radiotherapy (MRgRT) efficacy in treating adrenal gland metastasis, using stereotactic body radiation therapy (SBRT) to deliver high doses with minimal exposure to surrounding organs. The study, conducted at LMU University Hospital in Munich and Fondazione Policlinico Universitario Agostino Gemelli IRCCS in Rome, employed secure multiparty computation to ensure data privacy while enabling joint data analysis. The results documented the long-term effectiveness and safety of MRgRT, improving precision and reducing risks to nearby organs.

The EAP for [177Lu]Lu-PSMA-617 in PSMA-positive mCRPC patients showed similar PSA RRs and OS to the VISION trial, with comparable safety profiles despite more advanced disease and heavier ARSI treatment in EAP patients.

39 patients enrolled in a study (phase Ib, n=6; phase II, n=33) from Dec 2021 to Aug 2023. Two dose-limiting toxicities observed in the dose-escalation phase, both recovered after treatment. Recommended phase 2 dose of surufatinib set at 200 mg, qd, po. Efficacy analysis showed ORR of 97.1% and DCR of 100%. mPFS was 6.9 months, mOS was 21.1 months. Biomarker analysis revealed no significant influence of Ki-67, NSE, or ProGRP on tumor shrinkage, PFS, or OS. Safety analysis showed all patients experienced TEAEs, with 63.2% experiencing grade ≥3 TEAEs.

OBI-888, a humanized monoclonal IgG1 antibody targeting Globo H, was evaluated in a Phase I–II study for advanced solid tumors. The study found OBI-888 to be safe and well-tolerated, with no maximum tolerated dose (MTD) reached and low incidence of adverse effects. Disease stabilization was observed in 28.6% and 20% of patients in Parts A and B, respectively, suggesting a cytostatic effect. Antibody-dependent cell-mediated cytotoxicity (ADCC) was induced after each OBI-888 dose, indicating ADCC as a potential mechanism of action. However, overall complement-dependent cytotoxicity (CDC) activity was low. Given the limited antitumor activity despite prolonged disease stabilization in some patients, further development of OBI-888 is not planned.

The NURE-Combo trial showed neoadjuvant nivolumab plus nab-paclitaxel followed by adjuvant nivolumab was safe and active in muscle-invasive bladder cancer patients, achieving a 32.3% ypT0N0 response. The combination's safety profile was manageable, with no grade 4 or higher adverse events reported.

NURE-Combo trial evaluated nivolumab + nab-paclitaxel as neoadjuvant therapy for MIBC, followed by RC and adjuvant nivolumab. 31 patients enrolled; 32.3% achieved ypT0N0 response, 70.9% ypT≤1N0-x. 12-month EFS was 89.8%. First results suggest potential for immune-chemotherapy in MIBC.

Multiple myeloma (MM) remains incurable despite advances in treatment. Minimal residual disease (MRD) negativity, achieved through novel therapies, is a strong prognostic factor. MRD assessment methods, including next-generation flow cytometry and sequencing, are crucial for evaluating treatment response and guiding therapy, though their clinical application is still under evaluation.